No shutdowns: Abbott banks on medicine, vigilance to counter pandemic – News – Austin American-Statesman
With coronavirus infections surging in Texas, Gov. Greg Abbott traveled Thursday to Lubbock, a pandemic hot spot, to promote the state’s distribution of a new antibody therapy designed to limit the strain on hospitals.
The emphasis from now on, Abbott said, will be on improved treatment options plus an appeal to Texans to limit exposure by wearing face coverings, avoiding crowds — including extended family and friends — and keeping a safe distance from others in public.
“Statewide, we’re not going to have another shutdown,” Abbott said, adding that his previous orders forcing businesses to close and limiting the movement of people had severe consequences for the mental, physical and financial health of Texans.
Large social gatherings, not people going to work, are among the most common ways to spread COVID-19, he said.
“Shutdowns will not lead to the positive results that some people think,” Abbott said during a news conference at the Texas Tech University Health Sciences Center.
As the number of COVID-19 deaths in Texas neared 20,000 and hospitalizations continued a steady rise since early October, Democrats criticized Abbott’s approach as dangerously weak.
“I hope this new treatment is successful and saves lives, but Gov. Abbott should return power to local leaders so they can take decisive action to curb the rampant spread of COVID-19 in their communities,” said state Rep. Chris Turner, D-Grand Prairie and chairman of the House Democratic Caucus.
“The governor should get out of the way and let local leaders take measures to protect their communities,” Turner said.
Abbott called his first pandemic-related news conference in several weeks to tout the arrival of a monoclonal antibody therapy by Eli Lilly & Co. that will be distributed to hospitals across Texas, beginning with hot spot areas like Lubbock, El Paso and Amarillo.
Nursing homes and other sites should receive doses in the future as supplies get shipped to Texas from the federal government, he said.
Intended for those with early-stage COVID-19 and other health problems that put them at greater risk, the intravenous drug has been effective at keeping patients out of hospitals, which are under a growing strain in the current spike of infections, Abbott said.
Supplies of a second antibody therapy should begin flowing soon, Abbott said, adding that the state also is preparing to distribute two vaccines that could become available as early as December.
“The cavalry is coming,” Abbott said.
Thursday’s news conference did not include Lubbock County Judge Curtis Parrish, who tested positive for COVID-19 prior to Abbott’s visit. Parrish said he did not have “any of the major symptoms” and would continue working from home.
In late June and early July, when Texas was in the midst of a similar sharp rise in infections and hospitalizations, Abbott closed bars, reduced restaurant capacity and issued a face mask mandate in counties with more than 20 positive COVID-19 cases.
But unlike some Democratic governors who are tapping the brakes on reopening efforts as infections climb nationwide, Abbott said he’s banking on
COVID-19 Impact On Nephropathy Medicine Market 2020 and Key Players| Abbott, Bayer, Shionogi Inc. and Sanofi-aventis – MarketDesk
The MarketWatch News Department was not involved in the creation of this content.
Nov 12, 2020 (MarketResearch.biz via Comtex) —
The Global Nephropathy Medicine Market 2020 report offers a productive picture of the industry using synthesis, analysis, and also an outline of all advice derived from several sources. The pros have provided the various surfaces of the sector with an objective of pinpointing the manipulators of the global Nephropathy Medicine industry. The market report that is Nephropathy Medicine comprises the industry landscape and a market from a SWOT analysis of the prominent players. The Nephropathy Medicine information provided is comprehensive, and also the upshot of research.
This report covers the global Nephropathy Medicine industry landscape and its growth prospects within the next several years, the Report also brief deals with the merchandise cycle, comparing it to the important services and products across businesses which had been commercialized details the possibility for a variety of Nephropathy Medicine applications, talking about recent product inventions and provides a review on potential regional Nephropathy Medicine market stocks.
Access Sample Copy of Report (Use Company eMail ID for better coverage): https://marketdesk.org/report/global-nephropathy-medicine-market-mr/33180/#requestForSample
Major Key Players in Global Nephropathy Medicine Market Report: Sanofi-aventis, Shionogi Inc., Bayer, Abbott, Biogen Idec, Lilly, Astrazeneca, Alnylam, Genzyme Corporation, Novartis, BioTime, Roche
Key Types Segments and Categories:
Sub-Segments and Applications:
WHAT DOES THE Nephropathy Medicine REPORT CONTAIN?
This report examines from the global Nephropathy Medicine market with production, earnings, sales, export & import, market share, and increase the pace in the prediction period 2020 – 2026. The international Nephropathy Medicine market is divided on the grounds of both key players, product type, applications/end users, and regions. This report data provides Nephropathy Medicine players and executives a specific picture of the entire market. Besides that, also, it offers upcoming market movement Nephropathy Medicine challenges and opportunities in the market.
Enquire about this report at https://marketdesk.org/report/global-nephropathy-medicine-market-mr/33180/#inquiry
The analysis aims of the report are:
1. To investigate the global and key regions promote advantage and potential, challenge and Nephropathy Medicine opportunity, restraints, and dangers;
2. Targeted on the key players, also further study the sales, value and global Nephropathy Medicine market share and development plans in the future;
3. Worldwide key manufacturers, to specify, clarify and analyze the Nephropathy Medicine industry contest landscape, SWOT analysis;
4. To profile the key players and analyze their growth plans;
5. To define, clarify and predict the market by type, application, and regions;
6. To examine competitive improvements for example expansions, arrangements, new product launches, and acquisitions from the global Nephropathy Medicine industry;
7. To analyze each Nephropathy Medicine sub-market connected to individual expansion tendency and their contribution to the market;
8. The report clarifies a concise review of the worldwide Nephropathy Medicine market and explains the significant categorizations and terminologies of the publication subscribers on the industry;
9. To investigate the most notable players from North America, Europe, China, Japan, Middle East & Africa, India, South America, to
Biopharma stocks, which started the week on a firm footing, lost momentum mid-way through amid market-wide sell-off triggered by waning stimulus hopes.
The week was a quiet one from the perspective of news flow. Johnson & Johnson (NYSE: JNJ) was in the news for both right and wrong reasons. The company’s Phase 3 trial of its coronavirus vaccine was paused due to a trial participant contracting an unexplained illness. On a positive note, the company reported solid quarterly results and lifted its guidance.
Pfizer Inc. (NYSE: PFE), meanwhile, stayed above political pressure and provided a realistic timeframe for filing for emergency use authorization for its vaccine candidate.
Avenue Therapeutics Inc (NASDAQ: ATXI) shares fell from $11 to just under $4 after FDA rejected its opioid pain drug on safety concerns.
Clinical trial disappointments led to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Cyclerion Therapeutics Inc (NASDAQ: CYCN) shelving alpha-1 antitrypsin deficiency and sickle cell disease studies, respectively.
The week witnessed Nasdaq debuts by six biopharma companies, which collectively raised about $650 million in gross proceeds.
Here are the key catalysts for the unfolding week.
American College of Chest Physicians’ CHEST Annual Meeting 2020, being held virtually: Oct. 18-21
The Prostate Cancer Foundation’s 27th Annual Scientific Retreat: Oct. 20-23
IDWeek 2020: Oct. 20-25
American Society of Nephrology, or ASN, Kidney Week 2020 Annual Meeting: Oct. 22-25 (early programs scheduled for Oct. 19-21)
32nd European Organisation for Research and Treatment of Cancer-the National Cancer Institute- the American Association for Cancer Research, or EORTC-NCI-AACR, Symposium: Oct. 24-25
Zosano Pharma Corp’s (NASDAQ: ZSAN) NDA for its migraine drug Qtrypta has a PDUFA action date of Oct. 20. With the company disclosing in late September that it has received a discipline review letter, which raised two concerns about the clinical pharmacology section of the NDA, a decision by the d-day seems unlikely.
The FDA is set to rule on Spectrum Pharmaceuticals, Inc.’s (NASDAQ: SPPI) BLA for SPI-2012 to treat chemotherapy-induced neutropenia. The PDUFA date is Oct. 24.
Pfizer Inc. (NYSE: PFE) is scheduled to present at the ID Week 2020 full results of the pediatric Phase 2 proof-of-concept study of 20vPNC and detailed results from a Phase 2 proof-of-concept study of its potential first-in-class pentavalent meningococcal vaccine candidate.
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) will present at the ASN meeting results from the ILLUMINATE-B pediatric Phase 3 study of lumasiran in treating primary hyperoxaluria type 1.
Omeros Corporation (NASDAQ: OMER) is due to present final results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. The presentation, in the form of a webcast, is scheduled for Oct. 22.
Mustang Bio Inc (NASDAQ: MBIO), founded by Fortress Biotech (NASDAQ: FBIO), is scheduled to present at the Prostate Cancer Foundation’s annual scientific retreat initial Phase 1 data on CAR-T cell therapy MB-105 in patients with PSCA-positive metastatic castration-resistant prostate cancer. The presentation is fixed for Oct. 23.
View more earnings on IBB
Related Link: 9